Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 625 Stomach Neoplasms 75 Neoplasm Metastasis 59 Neoplasms 39 HER2-positive Breast Cancer 33 Breast Neoplasms, Male 30 Colorectal Neoplasms 28 Brain Neoplasms 25 Carcinoma, Non-Small-Cell Lung 21 Inflammatory Breast Neoplasms 20 Esophageal Neoplasms 20 Pancreatic Neoplasms 13 Triple Negative Breast Neoplasms 12 Lung Neoplasms 11 Endometrial Neoplasms 11 Ovarian Neoplasms 10 Colonic Neoplasms 10 Urinary Bladder Neoplasms 9 Rectal Neoplasms 9 Prostatic Neoplasms 9 Cardiotoxicity 8 Adenocarcinoma 8 Salivary Gland Neoplasms 7 Gallbladder Neoplasms 7 Breast Diseases 7 Biliary Tract Neoplasms 7 Adenocarcinoma Of Esophagus 7 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Sarcoma 6

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × Trastuzumab × Clear all

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡